Decoy Therapeutics preclinical data support once-weekly intranasal dosing for DCOY-CoV

Decoy Therapeutics says preclinical pharmacokinetic results show a single weekly intranasal dose could sustain protective exposure across upper airways and lungs for about a week; clinical trials expected to begin in 2027, with data scheduled for Sept 29 presentation.